|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DGLUCY |
Gene summary for DGLUCY |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DGLUCY | Gene ID | 80017 |
| Gene name | D-glutamate cyclase | |
| Gene Alias | C14orf159 | |
| Cytomap | 14q32.11 | |
| Gene Type | protein-coding | GO ID | GO:0006082 | UniProtAcc | Q7Z3D6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 80017 | DGLUCY | HTA11_347_2000001011 | Human | Colorectum | AD | 1.71e-08 | 5.09e-01 | -0.1954 |
| 80017 | DGLUCY | HTA11_696_2000001011 | Human | Colorectum | AD | 2.74e-05 | 4.41e-01 | -0.1464 |
| 80017 | DGLUCY | HTA11_866_2000001011 | Human | Colorectum | AD | 8.43e-08 | 5.25e-01 | -0.1001 |
| 80017 | DGLUCY | HTA11_546_2000001011 | Human | Colorectum | AD | 3.36e-06 | 7.12e-01 | -0.0842 |
| 80017 | DGLUCY | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.62e-03 | 3.92e-01 | 0.0674 |
| 80017 | DGLUCY | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.69e-51 | -8.85e-01 | 0.294 |
| 80017 | DGLUCY | HTA11_99999965104_69814 | Human | Colorectum | MSS | 1.20e-19 | -8.85e-01 | 0.281 |
| 80017 | DGLUCY | HTA11_99999971662_82457 | Human | Colorectum | MSS | 6.81e-50 | -8.85e-01 | 0.3859 |
| 80017 | DGLUCY | HTA11_99999973899_84307 | Human | Colorectum | MSS | 2.59e-15 | -8.85e-01 | 0.2585 |
| 80017 | DGLUCY | HTA11_99999974143_84620 | Human | Colorectum | MSS | 1.02e-52 | -8.85e-01 | 0.3005 |
| 80017 | DGLUCY | A001-C-207 | Human | Colorectum | FAP | 1.92e-02 | -2.56e-01 | 0.1278 |
| 80017 | DGLUCY | A015-C-203 | Human | Colorectum | FAP | 3.06e-30 | -1.21e-01 | -0.1294 |
| 80017 | DGLUCY | A015-C-204 | Human | Colorectum | FAP | 2.28e-04 | -1.81e-01 | -0.0228 |
| 80017 | DGLUCY | A014-C-040 | Human | Colorectum | FAP | 9.25e-05 | -3.87e-02 | -0.1184 |
| 80017 | DGLUCY | A002-C-201 | Human | Colorectum | FAP | 1.07e-12 | -2.97e-01 | 0.0324 |
| 80017 | DGLUCY | A001-C-119 | Human | Colorectum | FAP | 1.40e-04 | -2.09e-01 | -0.1557 |
| 80017 | DGLUCY | A001-C-108 | Human | Colorectum | FAP | 9.12e-15 | -1.19e-01 | -0.0272 |
| 80017 | DGLUCY | A002-C-021 | Human | Colorectum | FAP | 3.34e-04 | 3.00e-01 | 0.1171 |
| 80017 | DGLUCY | A002-C-205 | Human | Colorectum | FAP | 6.96e-21 | -5.87e-02 | -0.1236 |
| 80017 | DGLUCY | A001-C-104 | Human | Colorectum | FAP | 2.37e-02 | -3.59e-02 | 0.0184 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0043648 | Colorectum | AD | dicarboxylic acid metabolic process | 34/3918 | 96/18723 | 7.22e-04 | 7.28e-03 | 34 |
| GO:0006520 | Colorectum | AD | cellular amino acid metabolic process | 81/3918 | 284/18723 | 1.37e-03 | 1.19e-02 | 81 |
| GO:00436481 | Colorectum | FAP | dicarboxylic acid metabolic process | 24/2622 | 96/18723 | 2.88e-03 | 2.20e-02 | 24 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |